Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC Would Get Green Light To Go After Patent Thickets Under Bipartisan Senate Bill

Executive Summary

Legislation by Sens. Cornyn, R-TX, and Blumenthal, D-CT, in part reflects frustration over AbbVie’s tactics to preserve patent protection for Humira.

You may also be interested in...



Pfizer, Express Scripts Clash Over Biosimilar Formulary Placement

Pfizer VP blames rebate strategies of innovators for difficulty in getting biosimilars on formularies while Express Scripts official says it is all about net cost during House hearing on lowering Rx drug prices.

House Judiciary Committee Advances Four Drug Pricing Bills, Although Changes Are Still Likely

US committee will likely re-examine the language regarding the burden of proof in a bill prohibiting pay-for-delay settlements.

From Pricing To Patents: Hearing Signals A Potential New Focus

Sen. Cornyn recommended the Judiciary Committee initiate an inquiry into drug patents after a back-and-forth with AbbVie CEO Gonzalez over the Humira patent estate at the drug pricing hearing.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS125242

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel